DNA
Rawalpindi: The CEO of the Drug Regulatory Authority of Pakistan (DRAP), Mr. Asim Rauf, visited the Rawalpindi Chamber of Commerce and Industry (RCCI) and participated in a meeting of the Standing Committee on Pharmaceuticals. During the meeting, Mr. Rauf emphasized that ensuring the availability of quality medicines remains a top priority for the government. He highlighted efforts to streamline the processes for licensing and registration, making them more efficient and business-friendly to unlock the true potential of Pakistan’s pharmaceutical sector and drive export growth.
The meeting, presided over by RCCI President Mr. Usman Shaukat, also included Mr. Umar Farooq, Chairman of the Standing Committee on Pharmaceuticals. The committee members expressed their appreciation for DRAP’s proactive role in supporting the pharmaceutical industry and modernizing the regulatory framework.
Speaking on the occasion, Mr. Usman Shaukat stated, “The pharmaceutical sector holds immense potential to expand Pakistan’s exports. With a significant pharma cluster located in the Rawalpindi region, there is substantial demand for Pakistani medicines in Central Asia and Africa. Simplifying the processes for licensing, registration, and certification will be key to harnessing this potential.”
The meeting was attended by notable figures, including Group Leader Mr. Sohail Altaf, Senior Vice President Mr. Khalid Farooq Qazi, Vice President Mr. Fahad Barlas, Executive Committee members, and other distinguished members of the chamber.
The participants discussed strategies to enhance collaboration between DRAP and the pharmaceutical industry, address existing challenges, and capitalize on export opportunities to contribute to the national economy.
, Mr. Asim Rauf, visited the Rawalpindi Chamber of){kind=link}